The current price of TBPH is $17.03 — it has remained unchanged since the previous close. Data as of Sep 23, 2026.
TBPH is flat over the past week, flat over the past month and up 20.44% over the past year. The price is below its 200-day moving average of $17.16.
Analysts' average 12-month price target for TBPH is $17.00, which implies 0.18% downside from the current price. Individual estimates range from $17.00 to $17.00.
Of the 3 analysts covering Theravance Biopharma Inc, 3 rate it a hold. The overall consensus is neutral. Analyst ratings are opinions and do not guarantee future performance.
Theravance Biopharma Inc has a market capitalization of $882.64M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.
In its most recent quarterly report, Theravance Biopharma Inc posted a loss of $0.11 per share against an estimate of $0.0725, missing expectations by 251.72%. Upcoming reports are listed in the earnings calendar.
Theravance Biopharma Inc reported revenue of $20.73M in its most recent quarter, which has decreased by 20.86% compared with the same quarter a year earlier. Analysts had expected $22.49M.
Theravance Biopharma Inc has not paid any dividends over the past year.
Companies most comparable to Theravance Biopharma Inc include MannKind Corporation and Gossamer Bio, Inc.
In the latest trading session TBPH moved between $17.02 and $17.07, a range of 0.29% of its current price.
Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Theravance Biopharma Inc shows a buy rating today and a buy rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Theravance Biopharma Inc is buy. Technical ratings are indicators, not investment advice.
Over the past 52 weeks TBPH has traded between $13.08 and $21.03. The current price is 19.02% below its 52-week high.
Figures as of Sep 23, 2026. This information is provided for general purposes only and is not investment advice.